GlaxoSmithKline PLC (GSK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

GlaxoSmithKline PLC (GSK)

49.90

+0.01 (0.01%)

as of Sep 4, 2026, 7:59:56 pm Market Open.

82 watching

Investor Insights

Sep 7, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

GlaxoSmithKline PLC (GSK) is highlighted as a top investment pick by Stockchase Research Editor Michael O'Reilly, demonstrating resilience in the healthcare sector amidst market volatility. The company's recent earnings growth of 7% is notable, with financial metrics showing it trades at an appealing 11x earnings and 5.6x book value, alongside a robust return on equity (ROE) of 43%. Analysts have targeted a price of $54.31 for GSK, suggesting further upside potential with a recommended stop-loss strategy in light of ongoing disciplined investment practices. With a dividend yield of 3.3%, it continues to attract interest from investors looking for stability and growth potential in the pharmaceutical industry.

Consensus

Positive

Valuation

Undervalued

Similar

Pfizer, PFE

SELL

A volatile uptrend. The five year chart shows a "double top" has broken below the valley between the double top, which is a signal to sell.

TOP PICK

Growth in revenue, earnings, cash flow and earnings per share shall not better than its peers. Stable of products is very, very good. Good dividend.

BUY

Likes the pharmaceutical sector. The whole pharmaceutical area is cheap. Has a good pipeline. Pays a good dividend. Cheap. Well run.

DON'T BUY

A lot of trouble with these companies is having access to new products. They are so large now they have to continually feed the pipeline at an accelerated rate by acquiring at higher prices.

PAST TOP PICK

(A Top Pick May 8/06. Down 4%.) Pays at 3.5% dividend.

TOP PICK

Have increased the products in their pipeline. AA credit. 3.5% yield. Good long-term outlook.

BUY

5% dividend. The European pharmaceuticals have been in better shape generally than their US counterparts, so they are probably a better value story than this one. They’re looking to acquire to help their drug pipeline.

BUY

The 2nd largest pharmaceutical supplier globally. They also have good health care as well. Have an excellent pipeline, good dividend and good management.

BUY

Buying it now for 2005/2006 because, looking down the road, they are getting a 3.5/4% yield. A great way to play India.

TOP PICK

Dividend yield of more than 5%. They have a major portion of the pharmaceutical industry in India. May have to be patient.

WEAK BUY

They don't have a great pipeline. Have good profit margins on some vaccines and AIDS medications. The price is decent.

BUY

Likes, but prefers Johnson & Johnson.

BUY

Will take a few years for their products to come through, but you are getting a free cash flow yield of about 12%.

BUY

Prefers over US pharmaceuticals. Better situated globally.

TOP PICK

Good value. Yield of 2.3%. Good pipeline of products. Good R & D budget.

Showing 91 to 105 of 110 entries

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brian Madden

First Avenue Investment Counsel

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

GlaxoSmithKline PLC (GSK)